A Phase 3 interventional study of Brexpiprazole and Placebo in Agitation Associated With Alzheimer's Dementia and Alzheimer Dementia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-09-18.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Otsuka Holdings Co., Ltd..
Among the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2018, is one of 13 in phase 3, and was the 13th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →1 of the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 15+
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 345 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 265 across the 12 interventional studies, 450 across the 3 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
1 of the studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06875986Otsuka Pharmaceutical Co., Ltd.REXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's Dementia | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study compares the efficacy of 2 doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.
This is a phase 3, 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose trial designed to assess the efficacy, safety, and tolerability of brexpiprazole compared with placebo. The trial consists of a 12-week double-blind treatment period with a 30 day follow-up. The trial population will include male and female participants between 55 and 90 years of age (inclusive) with a diagnosis of probable Alzheimer's disease, who are residing either in an institutionalized setting or in a non-institutionalized setting where the participant is not living alone. This trial will analyze data gathered from approximately 330 participants at multiple countries. Participants may also be eligible to enter an active treatment extension trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants followed a titration schedule, to gradually increase their dose from 0.5 milligrams per day (mg/day) in the starting to 2 mg/day from Day 15. Participants continued to receive brexpiprazole 2 milligrams (mg), once daily until Week 12.
Drug: Brexpiprazole
Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 3 mg/day from Day 29. Participants continued to receive brexpiprazole 3 mg, once daily until Week 12.
Drug: Brexpiprazole
Participants received matching placebo, once daily for 12 weeks.
Other: Placebo
Oral tablets
Also known as: OPC-34712
Oral tablets
Change From Baseline to Week 12 in the CMAI Total Score
The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. A negative change from baseline indicates improvement. Mixed model repeated measures (MMRM) was used for the analysis. As prespecified in the statistical analysis plan (SAP), data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Agitation
CGI-S was used to rate the severity of agitation. The score ranges from 0 to 7 with response choices as, 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. The higher the value, the more severe the agitation. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
Time frame: Baseline and Week 12
Change From Baseline to Week 12 in CMAI Subscale Scores
The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. It consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding, as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The four subscales include 12, 6, 4, and 2 items, respectively. The score of the subscale is the sum of the individual items included in the subscale, so the score range for each of the 4 subscales is 0 to 84, 0 to 42, 0 to 28, and 0 to 14, respectively. Higher scores indicate worsening of the condition. A negative change from baseline=improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
Time frame: Baseline and Week 12
Change From Baseline in CMAI Total Score for Each Trial Visit During the Double-blind Treatment Period
The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, and 12
Change From Baseline in CGI-S for Each Trial Visit During the Double-Blind Treatment Period
CGI-S was used to rate the severity of agitation. The score ranges from 0 to 7 with response choices as, 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. The higher the value, the more severe the agitation. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, and 12
Clinical Global Impressions-Improvement (CGI-I) Score at Each Trial Visit During the Double-Blind Treatment Period
CGI-I is a 7-point scale that requires the clinician to assess whether a participant's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Higher scores indicate worse condition. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, and 12
CMAI Response Rate Assessed as Percentage of Participants With CMAI Response at Every Scheduled Trial Visit in the Double-Blind Treatment Period
The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
Time frame: Weeks 2, 4, 6, 8, 10, and 12
CMAI Response Rate Assessed as Percentage of Participants With CMAI Response Based on Improvement From Baseline in Agitation Status at Every Scheduled Trial Visit in the Double-Blind Treatment Period
The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, and 12
CGI-I Response Rate Assessed as Percentage of Participants With CGI-I Response at Every Scheduled Trial Visit in the Double-Blind Treatment Period
CGI-I is a 7-point scale that requires the clinician to assess whether a participant's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Higher scores indicate worse condition. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, and 12
A total of 345 participants were randomized, and participated in the study from 16 May 2018 to 1 June 2022.
| Milestone | Brexpiprazole 2 mg | Brexpiprazole 3 mg | Placebo |
|---|---|---|---|
| Started | 75 | 153 | 117 |
| Intent-to-treat population | 73 | 153 | 116 |
| Completed | 68 | 130 | 104 |
| Not completed | 7 | 23 | 13 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Adverse event | 1 | 11 | 5 |
| Withdrew: Site terminated by sponsor | 1 | 3 | 2 |
| Withdrew: Subject withdrew consent to participate | 5 | 5 | 3 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 |
| Withdrew: Reason not specified (not related to coronavirus disease 2019 [covid-19]) | 0 | 2 | 2 |
The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. A negative change from baseline indicates improvement. Mixed model repeated measures (MMRM) was used for the analysis. As prespecified in the statistical analysis plan (SAP), data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
| score on a scale | Brexpiprazole 2 and 3 mg | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in the CMAI Total Score | -22.6 ± 1.08 | -17.3 ± 1.44 |
CGI-S was used to rate the severity of agitation. The score ranges from 0 to 7 with response choices as, 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. The higher the value, the more severe the agitation. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
| score on a scale | Brexpiprazole 2 and 3 mg | Placebo |
|---|---|---|
| Change From Baseline to Week 12 in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Agitation | -1.20 ± 0.06 | -0.93 ± 0.08 |
The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. It consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding, as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The four subscales include 12, 6, 4, and 2 items, respectively. The score of the subscale is the sum of the individual items included in the subscale, so the score range for each of the 4 subscales is 0 to 84, 0 to 42, 0 to 28, and 0 to 14, respectively. Higher scores indicate worsening of the condition. A negative change from baseline=improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
| score on a scale | Brexpiprazole 2 and 3 mg | Placebo |
|---|---|---|
| Aggressive Behavior | -9.09 ± 0.42 | -7.13 ± 0.56 |
| Physically Nonaggressive Behavior | -6.45 ± 0.40 | -5.04 ± 0.53 |
| Verbally Agitated Behavior | -4.39 ± 0.31 | -3.14 ± 0.40 |
| Hiding and Hoarding | -1.50 ± 0.17 | -1.14 ± 0.23 |
The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
| score on a scale | Brexpiprazole 2 and 3 mg | Placebo |
|---|---|---|
| Change From Baseline at Week 2 | -5.76 ± 0.71 | -6.61 ± 0.90 |
| Change From Baseline at Week 4 | -12.1 ± 0.82 | -11.0 ± 1.06 |
| Change From Baseline at Week 6 | -16.2 ± 0.91 | -13.9 ± 1.19 |
| Change From Baseline at Week 8 | -19.4 ± 0.96 | -14.4 ± 1.28 |
| Change From Baseline at Week 10 | -22.2 ± 0.97 | -15.7 ± 1.29 |
| Change From Baseline at Week 12 | -22.6 ± 1.08 | -17.3 ± 1.44 |
CGI-S was used to rate the severity of agitation. The score ranges from 0 to 7 with response choices as, 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. The higher the value, the more severe the agitation. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
| score on a scale | Brexpiprazole 2 and 3 mg | Placebo |
|---|---|---|
| Change From Baseline at Week 2 | -0.21 ± 0.03 | -0.27 ± 0.04 |
| Change From Baseline at Week 4 | -0.53 ± 0.05 | -0.50 ± 0.06 |
| Change From Baseline at Week 6 | -0.74 ± 0.05 | -0.68 ± 0.07 |
| Change From Baseline at Week 8 | -0.97 ± 0.06 | -0.70 ± 0.08 |
| Change From Baseline at Week 10 | -1.14 ± 0.06 | -0.86 ± 0.08 |
| Change From Baseline at Week 12 | -1.20 ± 0.06 | -0.93 ± 0.08 |
CGI-I is a 7-point scale that requires the clinician to assess whether a participant's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Higher scores indicate worse condition. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
| score on a scale | Brexpiprazole 2 and 3 mg | Placebo |
|---|---|---|
| Week 2 | 3.70 ± 0.75 | 3.57 ± 0.69 |
| Week 4 | 3.19 ± 0.85 | 3.39 ± 0.87 |
| Week 6 | 2.92 ± 0.94 | 3.19 ± 0.95 |
| Week 8 | 2.80 ± 1.00 | 3.16 ± 1.01 |
| Week 10 | 2.62 ± 0.99 | 2.97 ± 1.00 |
| Week 12 | 2.66 ± 1.09 | 2.97 ± 1.12 |
The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
| percentage of participants | Brexpiprazole 2 and 3 mg | Placebo |
|---|---|---|
| >/= 20%: Week 2 | 11.3 | 13.2 |
| >/= 20%: Week 4 | 29.3 | 27.6 |
| >/= 20%: Week 6 | 43.1 | 37.9 |
| >/= 20%: Week 8 | 59.6 | 38.8 |
| >/= 20%: Week 10 | 65.8 | 45.7 |
| >/= 20%: Week 12 | 68.4 | 47.4 |
| >/= 30%: Week 2 | 3.62 | 3.51 |
| >/= 30%: Week 4 | 10.7 | 10.3 |
| >/= 30%: Week 6 | 22.7 | 20.7 |
| >/= 30%: Week 8 | 32.9 | 19.0 |
| >/= 30%: Week 10 | 38.2 | 24.1 |
| >/= 30%: Week 12 | 42.7 | 25.9 |
| >/= 40%: Week 2 | 1.81 | 1.75 |
| >/= 40%: Week 4 | 4.89 | 5.17 |
| >/= 40%: Week 6 | 10.7 | 8.62 |
| >/= 40%: Week 8 | 16.9 | 8.62 |
| >/= 40%: Week 10 | 20.9 | 11.2 |
| >/= 40%: Week 12 | 23.1 | 14.7 |
The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
| percentage of participants | Brexpiprazole 2 and 3 mg | Placebo |
|---|---|---|
| Week 2 | 8.14 | 14.0 |
| Week 4 | 20.4 | 19.0 |
| Week 6 | 33.8 | 26.7 |
| Week 8 | 44.0 | 31.0 |
| Week 10 | 50.2 | 34.5 |
| Week 12 | 52.4 | 37.1 |
CGI-I is a 7-point scale that requires the clinician to assess whether a participant's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Higher scores indicate worse condition. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.
| percentage of participants | Brexpiprazole 2 and 3 mg | Placebo |
|---|---|---|
| Week 2 | 4.98 | 5.26 |
| Week 4 | 21.8 | 12.1 |
| Week 6 | 35.1 | 23.3 |
| Week 8 | 44.4 | 24.1 |
| Week 10 | 52.4 | 33.6 |
| Week 12 | 52.4 | 40.5 |
Collected over From signing of informed consent up to end of study (Week 16). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole 2 mg | 0/75 (0%) | 0/73 (0%) | 5/73 (6.8%) |
| Brexpiprazole 3 mg | 1/153 (0.7%) | 6/153 (3.9%) | 10/153 (6.5%) |
| Placebo | 0/117 (0%) | 3/116 (2.6%) | 8/116 (6.9%) |
| Event | Brexpiprazole 2 mg | Brexpiprazole 3 mg | Placebo |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/73 | 2/153 | 0/116 |
| Hip fractureInjury, poisoning and procedural complications | 0/73 | 1/153 | 1/116 |
| Sars-Cov-2 test positiveInvestigations | 0/73 | 0/153 | 1/116 |
| Psychotic disorderPsychiatric disorders | 0/73 | 0/153 | 1/116 |
| Cardiac failureCardiac disorders | 0/73 | 1/153 | 0/116 |
| Covid-19Infections and infestations | 0/73 | 1/153 | 0/116 |
| PneumoniaInfections and infestations | 0/73 | 1/153 | 0/116 |
| FallInjury, poisoning and procedural complications | 0/73 | 1/153 | 0/116 |
| CachexiaMetabolism and nutrition disorders | 0/73 | 1/153 | 0/116 |
| DehydrationMetabolism and nutrition disorders | 0/73 | 1/153 | 0/116 |
| Event | Brexpiprazole 2 mg | Brexpiprazole 3 mg | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 5/73 | 10/153 | 8/116 |
Randomized Sample consisted of all participants who were randomized into this trial.
| Age, Continuous(years) | Brexpiprazole 2 mg | Brexpiprazole 3 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 74.3 ± 7.3 | 74.6 ± 8.0 | 73.0 ± 7.0 | 74.0 ± 7.5 |
| Sex: Female, Male(Participants) | Brexpiprazole 2 mg | Brexpiprazole 3 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 43 | 92 | 60 | 195 |
| Male | 32 | 61 | 57 | 150 |
| Ethnicity (NIH/OMB)(Participants) | Brexpiprazole 2 mg | Brexpiprazole 3 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 25 | 46 | 37 | 108 |
| Not Hispanic or Latino | 50 | 107 | 80 | 237 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Brexpiprazole 2 mg | Brexpiprazole 3 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 6 | 1 | 12 |
| White | 70 | 144 | 115 | 329 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Cohen-Mansfield Agitation Inventory (CMAI) Total Score(score on a scale) | Brexpiprazole 2 mg | Brexpiprazole 3 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 78.6 ± 15.5 | 81.2 ± 17.2 | 79.4 ± 17.6 | 80 ± 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from May 2018 to primary completion in May 2022, 48 months.
Results were first posted in Sep 2023, 1 year 3 months after primary completion.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 48 months is above that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →